Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial-Reference-Cited by-全球学者库

Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial

Published:2024-04 Issue:2 Volume:14 Page:
ISSN:2163-0402
Container-title:Neurology Clinical Practice
language:en
Short-container-title:Neur Clin Pract

Author:

Grill Joshua D.¹^ORCID,Raman Rema¹^ORCID,Ernstrom Karin¹^ORCID,Wang Shunran¹^ORCID,Donohue Michael C.¹^ORCID,Aisen Paul S.¹^ORCID,Karlawish Jason¹^ORCID,Henley David¹^ORCID,Romano Gary¹,Novak Gerald¹^ORCID,Brashear H. Robert¹,Sperling Reisa A.¹^ORCID

Affiliation:

1. Institute for Memory Impairments and Neurological Disorders (JDG), Departments of Psychiatry and Human Behavior and Neurobiology and Behavior, University of California Irvine, Irvine; Alzheimer's Therapeutic Research Institute (RR, KE, SW, MCD, PSA), University of Southern California, San Diego; University of Pennsylvania (JK), Philadelphia; Janssen Research & Development LLC (DH, GR, GN), Titusville, NJ; Indiana University School of Medicine (DH, HRB), Indianapolis; University of Virginia (HRB)...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical)

Link

https://www.neurology.org/doi/pdfdirect/10.1212/CPJ.0000000000200265

Reference45 articles.

1. NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

2. The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease

3. Hoffman La Roche. A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) (SKYLINE). U.S. National Library of Medicine. 2022. Accessed September 8, 2022. ClinicalTrials.gov.

4. Eli Lilly and Company. A Donanemab (LY3002813) Prevention Study in Participants with Alzheimer's Disease (TRAILBLAZER-ALZ 3). U.S. National Library of Medicine. 2021. Accessed September 8, 2022. ClinicalTrials.gov.

5. Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education